Cantargia AB (OSTO:CANTA)

kr 1.67 -0.045 (-2.62%) Market Cap: 415.18 Mil Enterprise Value: 355.37 Mil PE Ratio: 0 PB Ratio: 6.28 GF Score: 20/100

Q3 2024 Cantargia AB Earnings Call Transcript
Nov 15, 2024

kr1.9 (-0.99%)

Earnings
Q2 2024 Cantargia AB Earnings Call Transcript
Aug 28, 2024

kr3.99 (+1.17%)

Earnings
Q3 2023 Cantargia AB Earnings Call Transcript
Nov 10, 2023

kr3.61 (-10.20%)

Earnings
Q2 2023 Cantargia AB Earnings Call Transcript
Aug 22, 2023

kr4.25 (+1.58%)

Earnings
Q1 2023 Cantargia AB Earnings Call Transcript
May 23, 2023

kr4.89 (+5.89%)

Earnings
Q4 2022 Cantargia AB Earnings Call Transcript
Feb 23, 2023

kr6.03 (-16.49%)

Earnings
Q3 2022 Cantargia AB Earnings Call Transcript
Nov 10, 2022

kr3.59 (-7.33%)

Earnings
Q2 2022 Cantargia AB Earnings Call Transcript
Aug 30, 2022

kr4.14 (+0.15%)

Earnings
Cantargia AB Briefing on Update Recently Announced Rights Issue Transcript
Jul 07, 2022
Q1 2022 Cantargia AB Earnings Call Transcript
May 23, 2022

kr11.98 (+2.20%)

Earnings
Q4 2021 Cantargia AB Earnings Call Transcript
Feb 24, 2022

kr14.11 (+2.42%)

Earnings

Q2 2023 Cantargia AB Earnings Call Transcript

Aug 22, 2023 / 01:00PM GMT

Release Date Price: kr4.25 (+1.58%)

Transcript

GÃ;ran Forsberg Cantargia AB;CEO

¶-

Thank you so much. It's a pleasure to present Cantargia H1 report after what I believe has been a very strong period, as well as a very nice summer with a good news flow.

So to take you into the details then, starting out with significant events during or after this period or during the summer, we have presented new data both in pancreatic cancer, as well as non-small cell lung cancer, for our lead program, nadunolimab, and more specifically, it's been in chemotherapy combinations. And the presentations have been made at the two major cancer conferences, AACR and ASCO, and we're coming back to all these data. But in essence, they are certainly strong and have created lots of external interest and attention around our programs.

But based on these results, we're now also planning for a randomized controlled clinical Phase IIb trial in pancreatic cancer, where patients will get nadunolimab with chemotherapy or chemotherapy alone. And as we progress with the planning, there will be much more details around this trial.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.